Item 2.02. Results of Operations and Financial Condition.

On January 5, 2023, Bionano Genomics, Inc. (the "Company") issued a press release announcing certain preliminary performance results for the fourth quarter of 2022 and for the year ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits

Exhibit  Description

  99.1   Press Release issued January 5, 2023.
104      Inline XBRL for the cover page of this Current Report on Form 8-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses